Search

NIH WNV Monoclonal Antibodies Available for Licensing

NIAID, a component of the NIH, is making five novel neutralizing human monoclonal antibodies targeting West Nile virus (WNV) available for commercial licensing under 35 U.S.C. 209 and 37 CFR Part 404. The antibodies, which bind the WNV envelope protein, are in pre-clinical stage and are available alone or in combination, with accompanying nucleic acids, vectors, and host cells for production. HHS Reference No. E-200-2024-0 covers U.S. Provisional Patent Application (filed July 31, 2024) and PCT Application No. PCT/US2025/039922 (filed July 30, 2025).

DSHA Single Audit Identifies 8 Deficiencies, 6 Recurring

The Delaware Office of State Auditor published its Single Audit for the Delaware State Housing Authority (DSHA) covering fiscal year ended June 30, 2025. The audit identified eight significant deficiencies: two in internal controls over financial reporting and six regarding Uniform Guidance compliance. Six of these findings are recurring from fiscal years 2022–2024, indicating that prior corrective action plans were not effectively implemented, thereby increasing compliance risk. Findings include $168,055 in potentially fraudulent COVID-19 Emergency Rental Assistance, of which $82,709 remained uncollected as of June 30, 2025. DSHA has communicated a corrective action plan for each finding with target dates for remediation.